

Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London W1T 4TJ
Tel: +44 (0)20 7679 9538
Fax: +44(0)20 7679 9861
E-mail: r-codox-mivac@ctc.ucl.ac.uk
Website: www.ctc.ucl.ac.uk

6th June 2011

Ms Anna Bradnam
Hertfordshire REC
REC Office
Victoria House
Capital Park
Fulbourn
Cambridge CB21 5XB

Dear Ms Bradnam,

RE: A Phase II Single Arm Study of the use of CODOX-M/IVAC with Rituximab (R-CODOX-M/IVAC) in the treatment of patients with Diffuse Large B-Cell Lymphoma (DLBCL) or Burkitt's Lymphoma (BL) of International Prognostic Index High or High – Intermediate Risk

REC reference number: 05/Q0201/81
EudraCT Number: 2005-003479-19
Sponsor's Protocol number: UCL/05/134
Amendment 9.1 – 06.06.2011

On behalf of the sponsor, I request for authorisation of a substantial amendment made to the protocol of the above named trial.

For detailed changes made to the protocol, find enclosed 'Appendix 1 – List of detailed changes made to protocol v7.1'.

Please contact me should you have any queries.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Toyin Adedayo'.

Toyin Adedayo
Clinical Trials Coordinator

Enclosed: Annex 2, notification of substantial amendment form – 06.06.2011
 Annex 2 – Response to Section F
 Protocol Version 8.1, 31.05.2011 (tracked & untracked)
 Pregnancy Monitoring Information Sheet & ICF (patient) - version 1.0, 15.03.2011
 Pregnancy Monitoring Information Sheet & ICF (partner) - version 1.1, 15.03.2011
 List of Detailed changes made to Protocol v7.1
 Mabthera (Rituximab) SPC – 23.03.2010

cc – MHRA